Clinical trial
Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid…
NCT00268242 · The Cleveland Clinic, Other · Terminated
Key facts
| NCT number | NCT00268242 |
|---|---|
| Title | Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia |
| Official title | A Phase II Study of Gemcitabine/ Mitoxantrone in Patients With Acute Myeloid Leukemia in First Relapse |
| Lead sponsor | The Cleveland Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH Duke University |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | Gemcitabine Hydrochloride, Mitoxantrone Hydrochloride |
| Enrollment | 24 |
| Start date | Jan 1, 2006 |
| Primary completion | Aug 1, 2010 |
| Completion | Jul 1, 2011 |
| First posted | Dec 22, 2005 |
| Last update posted | Feb 22, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: